Luna Sun

560 total citations
25 papers, 253 citations indexed

About

Luna Sun is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Luna Sun has authored 25 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Dermatology, 15 papers in Immunology and Allergy and 10 papers in Physiology. Recurrent topics in Luna Sun's work include Dermatology and Skin Diseases (18 papers), Allergic Rhinitis and Sensitization (13 papers) and Asthma and respiratory diseases (10 papers). Luna Sun is often cited by papers focused on Dermatology and Skin Diseases (18 papers), Allergic Rhinitis and Sensitization (13 papers) and Asthma and respiratory diseases (10 papers). Luna Sun collaborates with scholars based in United States, Germany and Japan. Luna Sun's co-authors include Amy M. DeLozier, Jonathan I. Silverberg, Eric L. Simpson, Fabio P. Nunes, Kristian Reich, Robert Bissonnette, Andreas Wollenberg, Tracy Cardillo, Kenji Kabashima and Lawrence F. Eichenfield and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Luna Sun

23 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luna Sun United States	9	195	148	76	64	47	25	253
William Romero United States	9	321 1.6×	201 1.4×	94 1.2×	79 1.2×	62 1.3×	24	378
Renata Gontijo Lima United States	5	255 1.3×	146 1.0×	83 1.1×	60 0.9×	168 3.6×	8	358
Hajime Katsumata Japan	6	144 0.7×	178 1.2×	214 2.8×	21 0.3×	73 1.6×	7	339
J Ring Germany	7	233 1.2×	93 0.6×	45 0.6×	80 1.3×	30 0.6×	13	288
Edgardo Járes Argentina	8	92 0.5×	116 0.8×	76 1.0×	55 0.9×	29 0.6×	23	280
Autumn Guyer United States	8	99 0.5×	120 0.8×	47 0.6×	44 0.7×	27 0.6×	16	248
Laura Bonzano Italy	9	129 0.7×	141 1.0×	88 1.2×	39 0.6×	23 0.5×	22	231
Ali Al‐Janabi United Kingdom	10	126 0.6×	33 0.2×	30 0.4×	53 0.8×	100 2.1×	16	200
Hany Elmaraghy United States	9	315 1.6×	118 0.8×	82 1.1×	66 1.0×	261 5.6×	30	419
A. Galluccio Italy	9	153 0.8×	46 0.3×	33 0.4×	64 1.0×	188 4.0×	11	265

Countries citing papers authored by Luna Sun

Since Specialization

Citations

This map shows the geographic impact of Luna Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luna Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luna Sun more than expected).

Fields of papers citing papers by Luna Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luna Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luna Sun. The network helps show where Luna Sun may publish in the future.

Co-authorship network of co-authors of Luna Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Luna Sun. A scholar is included among the top collaborators of Luna Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luna Sun. Luna Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Corren, Jonathan, Stanley J. Szefler, Ellen Sher, et al.. (2024). Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology In Practice. 12(5). 1215–1224.e3. 18 indexed citations

Delbecque, Laure, et al.. (2024). Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale. Journal of Patient-Reported Outcomes. 8(1). 77–77. 1 indexed citations

Lio, Peter, April W. Armstrong, Jan Gutermuth, et al.. (2024). Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 14(7). 1929–1943. 2 indexed citations

Delbecque, Laure, et al.. (2024). Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis. Advances in Therapy. 41(4). 1512–1525. 6 indexed citations

Soung, Jennifer, Sonja Ständer, Jan Gutermuth, et al.. (2024). Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials. Journal of Dermatological Treatment. 35(1). 2329240–2329240. 8 indexed citations

Landewé, Robert, et al.. (2023). Robust analyses for radiographic progression in rheumatoid arthritis. RMD Open. 9(2). e002543–e002543.

Yosipovitch, Gil, Peter Lio, David Rosmarin, et al.. (2023). Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. British Journal of Dermatology. 190(2). 289–291. 16 indexed citations

Bieber, Thomas, Jacob P. Thyssen, Alan D. Irvine, et al.. (2023). Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clinical and Experimental Dermatology. 48(8). 881–888. 3 indexed citations

Taylor, Peter C., Yun-Fei Chen, Janet Pope, et al.. (2023). Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatology and Therapy. 10(2). 463–476. 2 indexed citations

10.

Reich, Kristian, Eric L. Simpson, Andreas Wollenberg, et al.. (2022). Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. British Journal of Dermatology. 188(2). 208–217. 11 indexed citations

11.

Masuda, Koji, Amy M. DeLozier, Andrew Buchanan, et al.. (2022). Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7. European Journal of Dermatology. 32(2). 237–243. 1 indexed citations

12.

Silverberg, Jonathan I., Robert Bissonnette, Kenji Kabashima, et al.. (2022). 33542 Stability of response prior to baricitinib downtitration or treatment withdrawal: Outcome from a substudy of BREEZE AD3. Journal of the American Academy of Dermatology. 87(3). AB205–AB205.

13.

Simpson, Eric L., April W. Armstrong, Mark Boguniewicz, et al.. (2022). Baricitinib 2 mg for the treatment of atopic dermatitis in North America : Long‐term efficacy and patient‐reported outcomes. Dermatologic Therapy. 35(12). e15954–e15954. 4 indexed citations

14.

Silverberg, Jonathan I., Amy M. DeLozier, Luna Sun, et al.. (2021). Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health and Quality of Life Outcomes. 19(1). 247–247. 18 indexed citations

15.

Silverberg, Jonathan I., Mark Boguniewicz, Jill Waibel, et al.. (2021). Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16. Dermatology and Therapy. 12(1). 137–148. 7 indexed citations

16.

Silverberg, Jonathan I., Eric L. Simpson, Andreas Wollenberg, et al.. (2021). Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders. JAMA Dermatology. 157(6). 691–691. 69 indexed citations

17.

Senna, Maryanne M., Amy McMichael, Julian Mackay‐Wiggan, et al.. (2021). 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study. Journal of the American Academy of Dermatology. 85(3). AB85–AB85. 1 indexed citations

18.

Wollenberg, Andreas, Mark Boguniewicz, Jeffrey B. Travers, et al.. (2020). Efficacy of Baricitinib in Patients with Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2). Journal of Allergy and Clinical Immunology. 145(2). AB190–AB190. 1 indexed citations

19.

Bingham, Clifton O., et al.. (2020). Conversion of Functional Assessment of Chronic Illness Therapy–Fatigue to Patient‐Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials. Arthritis Care & Research. 73(4). 481–488. 5 indexed citations

20.

Katz, Patricia, et al.. (2020). Estimation of Minimally Important Differences and Patient Acceptable Symptom State Scores for the Patient‐Reported Outcomes Measurement Information System Pain Interference Short Form in Rheumatoid Arthritis. ACR Open Rheumatology. 2(6). 320–329. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact